早期药物流产后的随访:一项随机对照试验的研究方案
该研究为在新西兰开展的多中心随机对照试验,拟纳入736名接受早期药物流产者,按1:1随机分配至低灵敏度尿妊娠试验自评随访组或系列血清βhCG血检随访组,主要结局为失访率,旨在比较两种随访方式的随访完成情况,并评估自评随访的安全性、可接受性。
要点
- 早期药物流产随访中,自评低灵敏度尿妊娠试验与系列血清βhCG血检的失访率比较尚缺乏随机对照证据。
- 该试验拟纳入736名参与者,按1:1随机分组,主要结局为失访。
- 样本量基于失访率从基线15%降至7.5%、90%把握度、双侧I类错误0.05计算。
核心结论
- 若自评随访可降低失访率、具有额外临床获益且安全、成本效益好、为妇女和临床医生所接受,预期将改变全球早期药物流产随访实践。
- 作者认为自评随访将作为以患者为中心的早期药物流产照护方案的一部分受到欢迎。
研究设计与样本
- 该研究为在新西兰开展的多中心随机对照试验,纳入符合条件的接受早期药物流产的妇女和孕妇。
- 参与者按1:1随机分配至自评随访组(低灵敏度尿妊娠试验结果自评)或血检随访组(系列血清βhCG血检)。
- 主要结局为失访。
- 为检测失访率从基线15%降至7.5%,设定90%把握度和双侧I类错误0.05,所需样本量为736名参与者,按1:1比例分组。
关键数值与推荐
- 主要结局失访率的检测目标为从基线15%降至7.5%,把握度90%,双侧I类错误0.05。
- 所需样本量为736名参与者,按1:1随机分组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early medical abortion (EMA) is safe and effective; an uncommon but crucial adverse outcome is ongoing live pregnancy. The best method of follow-up after EMA to detect ongoing pregnancy is a critical research gap. Few trials compare blood or urine pregnancy tests to ultrasound scans, and no trial compares these tests to each other. The aim is to evaluate the completeness of follow-up of two methods of follow-up after EMA- self-assessment with low-sensitivity urine pregnancy test result or serial serum βhCG blood tests. Secondary aims will evaluate whether self-assessment follow-up is safe and acceptable to patients and clinicians. METHODS: This is a multicentre randomised controlled trial in New Zealand. Eligible women and pregnant people having EMA will be randomised to self-assessment or blood test follow-up. The primary outcome is 'lost to follow-up.' To detect a decrease in 'lost to follow-up' rate from baseline of 15% to 7.5%, with 90% power and a two-sided type 1 error of 0.05, the sample size required is 736 participants, in a 1:1 ratio. DISCUSSION: If self-assessment reduces lost to follow-up, has additional clinical benefits, and is safe, cost-effective, and acceptable to women and clinicians, we anticipate change in EMA follow-up practice around the world. We think self-assessment will be welcomed as part of a patient-centred package of care following EMA. TRIAL REGISTRATION: This trial was prospectively registered with the Australia New Zealand Clinical Trials Registry (ANZCTR) on 21 August 2023, registration number ACTRN12623000890639; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384373.
引用
- Wise MR, MacDonald EJ, Knowles A, et al. Mate Whenua-follow-up after early medical abortion: study protocol for a randomized controlled trial. Trials. 2025. PMID: 40855501. doi:10.1186/s13063-025-09016-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。